Table 3

Clinical response by age group and overall

Age groupTotal
N=123
<18
N=43
≥18
N=80
Short-term treatment response
Improvement in symptom score*
 n365793
 Mean (SD)−21.7 (13.9)−22.2 (14.9)−22.0 (14.4)
Change in FEV1 (% predicted)†
 n3565100
 Mean (SD)13.9 (9.2)8.0 (8.3)10.0 (9.1)
<10% improvement FEV1 (L)‡
 n (%)10 (28.6)23 (35.4)33 (33.0)
Intravenous antibiotic within 30 days of completing intravenous for study PEx§
 n (%)2 (4.7)9 (11.3)11 (8.9)
Interim response: 3 months post-study PEx
Change in best FEV1 (% predicted) from 6 months prior to 3 months post PEx
 n3771108
 Mean (SD)1.6 (12.4)2.5 (7.9)2.2 (9.6)
<90% FEV1 baseline recovery¶
 n (%)5 (13.5)8 (11.3)13 (12.0)
Intravenous antibiotic within 90 days of completing intravenous for study PEx§
 n (%)10 (23.3)30 (37.5)40 (32.5)
Long-term response
Intravenous antibiotic within 180 days of completing Intravenous for study PEx
 n (%)23 (53.5)48 (60.0)71 (57.7)
Time to next intravenous antibiotic§ (days)
 Mean (SD)236.5 (190.3)234.7 (235.9)235.3 (220.2)
 Median174.0139.0143.0
 Min, Max22.0, 740.010.0, 984.010.0, 984.0
  • *Improvement in CF Respiratory Infection Symptom Score during treatment for study PEx.

  • †Absolute change in per cent predicted during study PEx treatment from visit 1 to visit 2.

  • ‡<10% relative change in FEV1 (L) during study PEx treatment (N=100, n<18=35, n≥18=65).

  • §Only intravenous antibiotic episodes occurring 7 or more days after end of treatment for study PEx are considered.

  • ¶Best FEV1 (% predicted) 3 months post-study PEx <0.90 of best FEV1 (% predicted) 6 months prior to study PEx4 (N=108, n<18=37, n≥18=71)

  • PEx, pulmonary exacerbation.